Imugene Ltd has released a press release.
New Complete Response in the Concurrent BTKi azer-cel Cohort
Earlier from Imugene
- First Complete Response in Concurrent BTKi azer-cel Cohort
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
- First Patient in BTKi Combination Cohort of azer-cel study
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract